Pazopanib Hydrochloride CAS 635702-64-6 Purity > 99.0% (HPLC) API Hoobkas

Lus piav qhia luv luv:

Lub npe tshuaj: Pazopanib Hydrochloride

CAS: 635702-64-6 Nr

Pom: Dawb rau me ntsis daj hmoov

Purity:> 99.0% (HPLC)

Tyrosine kinase receptor inhibitor rau kev kho mob siab heev rau lub raum cell carcinoma los yog cov nqaij mos siab heev sarcoma

API High Quality, Commercial Production

Inquiry: alvin@ruifuchem.com

Xa email rau peb

Product Detail

Yam khoom

Khoom cim npe

Nqe lus piav qhia:

Chaw tsim tshuaj paus Supply nrog High Purity thiab ruaj khov zoo
Lub npe tshuaj: Pazopanib Hydrochloride
CAS: 635702-64-6 Nr
Tyrosine kinase receptor inhibitor rau kev kho mob siab heev rau lub raum cell carcinoma lossis cov nqaij mos sarcoma uas tau txais kev kho mob ua ntej.
API High Quality, Commercial Production

Chemical Properties:

Tshuaj npe	Pazopanib Hydrochloride
Synonyms	Pazopanib HCl;GW786034 HCl;Votient;5-[[4-[(2,3-Dimethyl-2H-indazol-6-yl)(methyl)amino]pyrimidin-2-yl]amino]-2-methylbenzenesulfonamide Hydrochloride
CAS Nr	635702-64-6
CAT Number	RF-API 93
Tshuag xwm txheej	Nyob rau hauv Tshuag, ntau lawm Scale nce mus txog pua pua ntawm Kilograms
Molecular Formula	C21H23N7O2S.ClH
Molecular Luj	473.987 ib
Solubility	DMSO
Melting Point	300.0 ~ 304.0 ℃
Hom	Ruifu Tshuaj

Specifications:

Yam khoom	Specifications
Qhov tshwm sim	Dawb rau me ntsis daj hmoov
Kev txheeb xyuas	Infraed absorption spectrum ntawm cov qauv xeem yog concordant nrog tus qauv
Residue ntawm Ignition	≤0.50%
Txhua tus neeg impurity	≤ 0.30%
Tag nrho cov impurities	≤ 1.50%
Hnyav Hlau	≤10ppm
Purity / Analysis Method	≥99.0% (HPLC)
Test Standard	Enterprise Standard
Kev siv	API, Tyrosine kinase receptor inhibitor

Pob & Cia:

Pob: Lub raj mis, Aluminium ntawv ci hnab, Cardboard nruas, 25kg / Nruas, los yog raws li tus neeg yuav tsum tau muaj.

Cia txias:Khaws rau hauv cov thawv ntim khoom ntawm qhov chaw txias thiab qhuav;Tiv thaiv los ntawm lub teeb, noo noo thiab kab tsuag.

Qhov zoo:

FAQ:

Daim ntawv thov:

Pazopanib Hydrochloride (CAS 635702-64-6) yog ib tug multi-tyrosine kinase inhibitor ntawm vascular endothelial kev loj hlob receptor (VEGFR)-1, VEGFR-2, VEGFR-3, platelet-derived growth factor receptor (PDGFR)-α thiab - β, fibroblast kev loj hlob zoo receptor (FGFR)-1 thiab -3, cytokine receptor (Kit), interleukin-2 receptor-inducible T-cell kinase (Itk), lymphocyte-specific protein tyrosine kinase (Lck), thiab transmembrane glycoprotein receptor tyrosine kinase (cFms).Hauv vitro, pazopanib inhibited ligand-induced autophosphorylation ntawm VEGFR-2, Khoom siv, thiab PDGFR-beta receptors.Hauv vivo, pazopanib inhibited VEGF-induced VEGFR-2 phosphorylation hauv nas ntsws, angiogenesis hauv tus qauv nas, thiab kev loj hlob ntawm qee tus tib neeg qog xenografts hauv nas.Nws tau pom zoo rau lub raum cell carcinoma los ntawm US Food and Drug Administration nyob rau hauv 2009 thiab yog ua lag luam nyob rau hauv lub lag luam npe Votient los ntawm cov tshuaj cov chaw tsim tshuaj paus, GlaxoSmithKline.Votient yog ib qho kinase inhibitor qhia rau kev kho mob ntawm cov neeg mob uas muaj: 1) advanced renal cell carcinoma.2) cov ntaub so ntswg sarcoma siab heev uas tau txais kev kho mob ua ntej.